证券代码：688617 证券简称：惠泰医疗 公告编号：2025-030 深圳惠泰医疗器械股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | | --- | --- | --- | --- | | | | 通股份上市日 | | | 2025/6/18 | 2025/6/19 | 2025/6/19 | 2025/6/19 | 一、 通过分配、转增股本方案的股东大会届次和日期 本次利润分配及转增股本方案经公司2025 年 5 月 13 日的2024年年度股东大会 审议通过。 二、 分配、转增股本方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 公司存在首发战略配售股份，首发战略配售股份已全部上市流通 是否涉及差异化分红送转：否 每股分配比例，每股 ...

Core Viewpoint - The Chinese innovative pharmaceutical industry is undergoing a transformation driven by capital empowerment, focusing on mergers and acquisitions (M&A) to enhance global competitiveness and innovation capabilities [1][9][10] Group 1: Mergers and Acquisitions - The acquisition of Transcenta by Baike Biopharma exemplifies the strategic alignment of technology and industry, showcasing the logic of external M&A to quickly acquire products and leverage partner resources [1][2] - M&A is becoming a long-term mainstream logic in the capital market, enabling systematic integration of industry resources and optimizing the configuration of biotech R&D efficiency with large pharmaceutical companies' commercialization capabilities [2][4] - The NewCo model, where companies spin off pipelines to form joint ventures with capital, is emerging as a more aggressive internationalization path [3][9] Group 2: Market Dynamics and Policy Support - The innovative drug M&A market is heating up due to supportive policies and increasing industry concentration, with initiatives aimed at reducing transaction costs and enhancing the quality of innovative drugs [4][9] - The decline in primary market financing and the slowdown of secondary market IPOs are prompting innovative pharmaceutical companies to adjust their development strategies [4][8] - The establishment of long-term capital initiatives, such as a 20-year national venture capital fund, indicates a recognition of the importance of long-term funding in driving technological innovation [8] Group 3: Investment Strategies and Evaluation - Public funds are developing multi-dimensional evaluation models to guide innovative drug M&A, focusing on core indicators such as technological barriers, pipeline potential, commercialization ability, and internationalization capability [7] - The emphasis on clinical advancement efficiency is crucial, as it directly impacts the pipeline monetization cycle [7] - The trend of "License-out" and "NewCo" models reflects a transitional strategy for domestic pharmaceutical companies to engage in overseas development while enjoying greater rights [9][10]

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

Group 1 - The A-share market showed mixed performance on June 10, with the Sci-Tech Innovation Pharmaceutical Index ETF (588700) declining by 0.38% and a trading volume exceeding 30 million yuan [1] - The Sci-Tech Innovation Pharmaceutical Index ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in biopharmaceuticals, biomedical engineering, and related sectors [1] - The Chinese government has issued guidelines to improve basic medical insurance and commercial health insurance, aiming to better meet the multi-level medication needs of the public [1] Group 2 - The innovative drug sector has experienced rapid growth in product revenue and external licensing over the past three years, with significant business development (BD) transactions occurring this year [2] - There is a trend of the innovative drug market expanding to the overall sector, with a focus on companies with large product volumes and BD expectations [2]

Core Viewpoint - Huatai Medical (688617) has announced adjustments to its 2024 profit distribution plan, including cash dividends and capital reserve share increases, following the completion of the third vesting period of its 2021 restricted stock incentive plan [1][2]. Company Announcements - Huatai Medical will distribute a cash dividend of RMB 17.50 per 10 shares (including tax) and will increase its share capital by 4.5 shares for every 10 shares held, resulting in a total cash distribution of RMB 170,189,064.50 (including tax) and an increase of 43,762,902 shares in capital reserve [1][2]. - The total number of shares will increase from 97,081,956 to 141,013,796 after the adjustments [1]. - The completion of the third vesting period of the restricted stock incentive plan resulted in the listing of 168,938 shares, with the total share capital increasing from 97,081,956 to 97,250,894 shares [2]. - The controlling shareholder and actual controller of the company remain unchanged after the stock changes [2]. - CITIC Securities conducted a compliance inspection of Huatai Medical's operations from January 1, 2024, to the date of the inspection, confirming that the company meets the requirements set by the China Securities Regulatory Commission and the Shanghai Stock Exchange [2].

Group 1 - The core viewpoint of the article is that Shenzhen Huitai Medical Devices Co., Ltd. has been found to be compliant in various aspects of corporate governance, internal control, and information disclosure during the ongoing supervision period by CITIC Securities [1][2] Group 2 - The onsite inspection covered aspects such as corporate governance, internal control, information disclosure, independence, fundraising usage, related party transactions, external guarantees, major external investments, and operational status [1] - The company’s governance structure and internal control systems were found to be complete and compliant, with effective execution of relevant regulations by directors, supervisors, and senior management [1] - During the inspection, it was confirmed that the company fulfilled its information disclosure obligations accurately and completely, with no false records or significant omissions [1] - The company maintained independence from its controlling shareholders and related parties, with no violations regarding the appropriation of company funds [1] - Fundraising was properly managed, with funds stored in dedicated accounts and no unauthorized changes in usage [1] - There were no violations found in related party transactions, external guarantees, or major external investments [1] - The company has maintained a stable operational status and profitability since its listing, with no significant changes in its business model [1] - Recommendations were made for the company to continue improving its governance structure and comply with relevant regulations regarding fundraising and project implementation [1]

2024年持续督导工作现场检查报告 中信证券股份有限公司 关于深圳惠泰医疗器械股份有限公司 根据《上海证券交易所上市公司持续督导工作指引》等有关法律、法规的规 定，中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为正在履 行深圳惠泰医疗器械股份有限公司（以下简称"惠泰医疗"、"公司"）持续督 导工作的保荐人，对公司 2024 年 1 月 1 日至本次现场检查期间（以下简称"本 持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报 告如下： （四）现场检查人员 张刚、赵岩 一、本次现场检查的基本情况 （五）现场检查内容 （一）保荐人 公司治理和内部控制情况，信息披露情况，公司的独立性以及控股股东、实 际控制人及其他关联方资金往来情况，募集资金使用情况、募投项目的实施情况， 关联交易、对外担保、重大对外投资情况、经营状况等。 中信证券股份有限公司 （二）保荐代表人 孙炎林、赵岩 （三）现场检查时间 2025 年 5 月 7 日、6 月 3 日 6、查阅本持续督导期间公司募集资金使用台账、募集资金专户银行对账单 等资料，查看募投项目实施情况； 7、核查本持续督导期间公司发生的关联交易、对 ...

Core Viewpoint - Shenzhen Huatai Medical Devices Co., Ltd. has announced adjustments to its 2024 profit distribution cash dividend total and capital reserve share increase total due to changes in its total share capital resulting from the completion of the third vesting period of the B-class restricted stock incentive plan [1][2][3] Group 1: Adjusted Profit Distribution and Capital Increase - The adjusted cash dividend distribution is set at RMB 17.50 per 10 shares (including tax) [1][3] - The total cash distribution amount is estimated to be RMB 170,189,064.50 (including tax), based on a total share capital of 97,250,894 shares [1][3][4] - The total capital reserve share increase is calculated to be 43,762,902 shares, increasing the total share capital to 141,013,796 shares [4] Group 2: Reasons for Adjustment - The adjustment is due to the issuance of an additional 168,938 shares following the completion of the third vesting period of the B-class restricted stock incentive plan [2][3] - The total share capital increased from 97,081,956 shares to 97,250,894 shares after the registration of the new shares on May 30, 2025 [2][3]

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-028 深圳惠泰医疗器械股份有限公司 关于公司 2021 年限制性股票激励计划首次授予及预留 部分授予 B 类限制性股票第三个归属期第一次归属结 果暨股份上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 168,938股。 本次股票上市流通总数为168,938股。 本次股票上市流通日期为2025 年 6 月 6 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，深圳惠泰医疗器械股份有限公司（以下 简称"公司"）于 2025 年 6 月 3 日收到中国证券登记结算有限责任公司上海分公 司出具的《证券变更登记证明》，公司已完成 2021 年限制性股票激励计划（以下 简称"本激励计划"）首次授予及预留部分授予 B 类限制性股票第三个归属期第 一次归属的股份登记工作。现将有关情况公告如下： 一、本激励计划已履行的决策程序 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-029 深圳惠泰医疗器械股份有限公司 关于调整 2024 年度利润分配现金分红总额及资本公 积转增股本总额的公告 调整后资本公积金转增股本总额：公司总股本为 97,250,894 股，以 此计算合计拟转 增股本 43,762,902 股，转增后公司 总股本将增加至 141,013,796 股（具体以中国证券登记结算有限责任公司上海分公司最终登记 结果为准，如有尾差，系取整所致）。 本次调整原因：深圳惠泰医疗器械股份有限公司（以下简称"公司"） 因 2021 年限制性股票激励计划首次授予及预留部分授予 B 类限制性股票第 三个归属期第一次归属完成，新增股份 168,938 股，2025 年 5 月 30 日已在 中国证券登记结算有限责任公司上海分公司办理完毕新增股份的登记手续， 变更后公司的总股本由 97,081,956 股增加至 97,250,894 股。公司按照在实施 权益分派的股权登记日前公司总股本发生变动的，拟维持每股分配及转增比 例不变的原则，对 2024 年度利润分配预案的现金分红总额及转增股本总额 进行相应调整。 一、调整前利润分配、 ...